Sensei Biotherapeutics (NASDAQ:SNSE) Issues Earnings Results, Beats Expectations By $0.01 EPS

Sensei Biotherapeutics (NASDAQ:SNSE) released its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01, Yahoo Finance reports.

Sensei Biotherapeutics Price Performance

Sensei Biotherapeutics stock traded down $0.04 during trading hours on Wednesday, hitting $0.61. 10,978 shares of the company traded hands, compared to its average volume of 132,850. The firm has a market cap of $15.30 million, a P/E ratio of -0.54 and a beta of 0.03. The company has a quick ratio of 12.07, a current ratio of 12.07 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $0.67 and its two-hundred day simple moving average is $0.91. Sensei Biotherapeutics has a 1-year low of $0.51 and a 1-year high of $1.94.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SNSE. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Sensei Biotherapeutics in a research note on Wednesday. Citigroup reiterated a “buy” rating and set a $4.00 price objective on shares of Sensei Biotherapeutics in a research note on Monday, June 3rd. Finally, Stephens reiterated an “overweight” rating and set a $5.00 price objective on shares of Sensei Biotherapeutics in a research note on Friday, May 24th.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.